1. Introduction: Overcoming Challenges in LDL-C Target Achievement
Despite the widespread use of statins, many high- and very-high-risk cardiovascular patients fail to reach their strict LDL-C goals due to treatment limits or statin intolerance. Managing dyslipidemia effectively often requires addressing both endogenous cholesterol production and intestinal absorption simultaneously.
Bempo Plus, manufactured by Zein Pharma, combines two non-statin lipid-lowering therapies into a single daily fixed-dose film-coated tablet:
- Bempedoic Acid (180 mg): Acts in the liver by inhibiting adenosine triphosphate-citrate lyase (ACL), suppressing cholesterol biosynthesis upstream of HMG-CoA reductase.
- Ezetimibe (10 mg): Acts in the small intestine by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter, inhibiting dietary and biliary cholesterol absorption.
This complementary dual-mechanism delivers comprehensive lipid control while remaining suitable for statin-intolerant patients.
2. Guideline Recommendations: ESC/EAS 2025 Focused Update
In the latest ESC/EAS Guidelines for the Management of Dyslipidaemias, combination non-statin therapy holds a prominent place in pharmacological cholesterol reduction algorithms:
- Class 2a Recommendation (Level of Evidence: C): The addition of Bempedoic Acid to the maximally tolerated dose of a statin, with or without Ezetimibe, should be considered in patients at high or very high cardiovascular risk to achieve LDL-C goals.
- Combination Potency Benchmarks:
- Bempedoic Acid + Ezetimibe (BA + EZE): Provides an average 38% reduction in LDL-C.
- High-Intensity Statin + Ezetimibe + Bempedoic Acid: Achieves up to a 68% reduction in baseline LDL-C.
3. Clinical Study Highlights: Phase 3 Trial 053
The 053 Clinical Trial was a 12-week, randomized, double-blind, Phase 3 study in 301 patients with heterozygous familial hypercholesterolemia (HeFH), established cardiovascular disease (CVD), or multiple CVD risk factors receiving maximally tolerated statins.
Primary Endpoint: Robust LDL-C Reductions (p < 0.001)
- Bempo Plus: -36.0% reduction from baseline ($-38.0\%$ placebo-corrected).
- Ezetimibe Monotherapy: -23.2% reduction.
- Bempedoic Acid Monotherapy: -17.2% reduction.
- Placebo: +2.0% increase.
Bempo Plus demonstrated statistically superior LDL-C lowering compared to both Ezetimibe (p < 0.001) and Bempedoic Acid monotherapy (p < 0.001).
Dual Advantage: Anti-Inflammatory Impact on hsCRP
In addition to lipid lowering, Bempo Plus significantly reduced high-sensitivity C-reactive protein (hsCRP), a core systemic marker of vascular inflammation:
- Bempo Plus: -35.1% reduction in hsCRP from baseline.
- Bempedoic Acid: -31.9% reduction.
- Ezetimibe: -8.2% reduction.
- Placebo: +21.6% increase.
4. Product Specifications Summary
| Feature | Specification |
| Brand Name | Bempo Plus |
| Active Ingredients | Bempedoic Acid ($180\text{ mg}$) + Ezetimibe ($10\text{ mg}$) |
| Dosage Form | Film-coated tablets |
| Pack Size | 30 Film-Coated Tablets |
| Mechanism of Action | Dual ACL enzyme inhibitor & NPC1L1 absorption blocker |
| Manufacturer | Zein Pharma (Tartous – Syria) |
5. Dosage & Clinical Administration
- Standard Dosage: One Bempo Plus tablet (180 mg / 10 mg) taken orally once daily.
- Administration: Can be taken with or without food.
- Target Patient Populations: Patients with primary hyperlipidemia, established ASCVD, or statin intolerance who need to reach strict LDL-C thresholds.
Disclaimer: This medical overview is prepared for healthcare professionals and educational reference. Treatment choices should always follow physician assessment and local prescribing information.
